Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.3 , No. 3, Publication Date: May 25, 2016, Page: 55-59
 and Acute Myelogenous Leukemia (AML). This work was conducted at Tripoli Medical Center (TMC), department of Pediatric Oncology to study child hood leukemia in diagnosed 50 Libyan leukemic children. This retrospective study was undertaken covering a period between 1997 and 2003, to describe the prevalence of most common types of leukemia and its relation to the family history, age and sex. It is also evaluated the rate of remission after chemotherapy. The results showed that ALL (73%) and AML (26%) are the most common types of leukemia occur in these children. Regardless gender type, the highest percentage was recorded between one month and 8 years of age. The incidence in males is higher than that in females, meantime no relation between incidence of leukemia and family history was observed. The highest cases of leukemia in these children were clinically reported in 1997 (24%) and in 2003 (22%). The most common symptoms reported among them were specifically fever, weight loss and fatigue. Chemotherapy protocols applied resulted in remission in 88% of cases while deaths was represented in 12% of all cases. In summary, further studies are needed to identify patients who are at high risk from failing of conventional therapeutic approach. Therefore, afforded the highest chance for a cure from childhood leukemia.&picture=http://www.aascit.org/aascit/decorators/img/journal/906.jpg)
| [1] | Hanan Abushwereb, Pharmacology and Clinical Pharmacy Department, University of Tripoli, Faculty of Pharmacy, Tripoli, Libya. |
| [2] | Salem Zaroug, Pediatric Oncology Department, Tripoli Medical Center, Tripoli, Libya. |
| [3] | Salwa Othman, Pharmacology and Clinical Pharmacy Department, University of Tripoli, Faculty of Pharmacy, Tripoli, Libya. |
Leukemia is a cancer of the tissues that produce blood cells resulting in abnormal cells. Several forms of leukemia are reported, two of which are particularly common in children between ages of one month up to 16 years. These are known as Acute Lymphocytic Leukemia (ALL) and Acute Myelogenous Leukemia (AML). This work was conducted at Tripoli Medical Center (TMC), department of Pediatric Oncology to study child hood leukemia in diagnosed 50 Libyan leukemic children. This retrospective study was undertaken covering a period between 1997 and 2003, to describe the prevalence of most common types of leukemia and its relation to the family history, age and sex. It is also evaluated the rate of remission after chemotherapy. The results showed that ALL (73%) and AML (26%) are the most common types of leukemia occur in these children. Regardless gender type, the highest percentage was recorded between one month and 8 years of age. The incidence in males is higher than that in females, meantime no relation between incidence of leukemia and family history was observed. The highest cases of leukemia in these children were clinically reported in 1997 (24%) and in 2003 (22%). The most common symptoms reported among them were specifically fever, weight loss and fatigue. Chemotherapy protocols applied resulted in remission in 88% of cases while deaths was represented in 12% of all cases. In summary, further studies are needed to identify patients who are at high risk from failing of conventional therapeutic approach. Therefore, afforded the highest chance for a cure from childhood leukemia.
Keywords
Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Pediatric Oncology, Libyan Children
Reference
| [01] | Draper G. J., Kroll M. E, Stiller C. A. (1994). Childhood cancer. Cancer Surv.19 –20: 493-517. |
| [02] | Chiorazzi, N., Rai, K. R., and Ferrarini, M. (2005). Chronic lymphocytic leukemia. N Engl J Med.; 352: 804–815. |
| [03] | Watson, L., Wyld, P., and Catovsky, D. (2008). Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol.; 81: 253–258. |
| [04] | Jemal A, Murray T, Samuels A, et al. (2003). Cancer Statistics 2003. CA Cancer J Clin.; 53: 5–26. |
| [05] | Wilkinson JD, Gonzalez A, Wohler-Torres B, Fleming LE, MacKinnon J, Trapido E, Button J, Peace S. (2005). Cancer incidence among Hispanic children in the United States. Rev Panam Salud Publica.; 18: 5–13. |
| [06] | Ma S. K., Chan G. C., Ha S. Y., et al. (1997). Clinical presentation, hematological features, and treatment outcome of childhood acute lymphoblastic leukemia: a review of 73 cases in Hong Kong. Hematol Oncol. 15: 141-149. |
| [07] | Pui C. H., Ribiero R. C. (2003). International collaboration on childhood leukemia. Int. J. Hematol. 78: 383-389. |
| [08] | Bhayat F, Das-Gupta E, Smith C, et al; (2009). The incidence of and mortality from leukaemias in the UK: a general BMC Cancer Jul 26; 9: 252. |
| [09] | Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringdén O, Stone JA, Bortin MM. (1994). Identical-twin bone marrow transplants for leukemia. Ann Intern Med.; 120 (8): 646-52. |
| [10] | Emily M. Fredericks, Nataliya Zelikovsky, Isabelle Aujoulat, Anna Hames, Jo Wray (2014). Post-transplant Adjustment – The Later Years. Pediatr Transplant.18 (7): 675–688. |
| [11] | Mertens A. C., Wen W., Davies S. M., et al. (1998). Congenital abnormalities in children with acute leukemia: a report from the Children's Cancer Group. J Pediatr. 133: 617-623. |
| [12] | Pui C-H, Evans WE, Gilbert JR. (1998.) Meeting report: International Childhood ALL Workshop: Memphis, TN Leukemia.; 12: 1313–1318. |
| [13] | Greaves M. F.(1997). Etiology of acute leukemia. Lancet 19: 349 (9048): 344-9. |
| [14] | Hayashi Y. (2003). Gene expression profiling in childhood acute leukemia: progress and perspectives. Int J Hematol. 78: 414-420. |
| [15] | Ribeiro RC, Broniscer A, Rivera GK, et al. (1997). Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts. Leukemia.; 11: 1493–1496. |
| [16] | Jones L. K., Saha V. (2005). Philadelphia positive acute lymphoblastic leukemia of childhood. Br J Haematol 130 (4): 489-500. |
| [17] | Birch J. M. (1999). Genes and cancer. Arch Dis Child. 80: 1-3. |
| [18] | Bradbury J. Brighter future for children with T-ALL (2003). Lancet Oncol. 4: 650-652. |
| [19] | Chessells J. M., Veys P., Kempski H., et al. (2003). Long term follow-up of relapsed childhood acute lymphoblastic leukemia. Br. J. Haematol. 123: 396-405. |
| [20] | Craig F. E. (2003). Bone marrow evaluation in pediatric patients. Semin Diagn Pathol. 20: 237-246. |
| [21] | David S. Ziegler, Luciano Dalla Pozza, Keith D. Waters and Glenn M. Marshall (2005). Advances in childhood leukaemia: successful clinical-trials research leads to individualized therapy. The Medical Journal of Australia (MJA); 182 (2): 78-81. |
| [22] | DiAngio G. J. (2001). Old man river. The flow of pediatric oncology. Hematol Oncol Clin North Am. 15: 599-607. |
| [23] | Downing J. R., Shannon K. M (2002). Acute leukemia: a pediatric perspective. Cancer Cell. 2: 437-445. |
| [24] | Gusbi et al. (2014). Risk factors of childhood leukemia at Tripoli medical center in Libya. American Journal of Pharmacy and Pharmacology 1 (2): 17-22. |
| [25] | Hiroto I, Mel G, and Charles G. M. (2013). Acute lymphoblastic leukaemia. Lancet. 381 (9881). |
| [26] | Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975 -2008 National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/ based on November 2010 SEER data submission, posted to the SEER web site, 2011. |
| [27] | Kimberly J. Johnson, Susan E. Carozza, et al., 2009 Parental age and risk of childhood cancer: A pooled analysis. Epidemiology. 20 (4): 475–483. |
| [28] | Lee S., Kim Y. J., Min C. K., et al (2005). The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 105 (9): 3449-57. |
| [29] | Manera R., Ramirez I., Mullins J., Pinkel D. (2000). Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype. Leukemia. 14: 1354-1361. |
| [30] | National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. Available at: http://www.seer.cancer.gov Accessed February 4, 2005. |
| [31] | Plasschert S. L., Kamps W. A., Vellenga E., de Vries E. G., de Bont E. S. (2004). Prognosis in childhood and adult acute lymphoblastic leukemia: a question of maturation? Cancer Treat Rev. 30: 37-51. |
| [32] | Pui C. H., Evans W. E. (2006). Treatment of acute lymphoblastic leukemia. N Engl. J. Med. 12: 354 (2): 166-78. |
| [33] | Rivera G. K., Pinkel D., Simone J. V., et al (1993). Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med. 329 (18): 1289-95. |
| [34] | Robison L. L., Buckley J. D., Bunin G. (1995). Assessment of environmental and genetic factors in the etiology of childhood cancers: the Children’s Cancer Group epidemiology program. Environ. Health Perspect. 103 (suppl 6): 11-116. |
| [35] | Satake N. (2006). Acute Lymphoblastic Leukemia. eMedicine - Acute Lymphoblastic. Leukemia Article by Noriko Satake, MD. htm. |
| [36] | Schrappe, M., Reiter, A., Ludwig, W. D., Harbott, J., Zimmermann, M., Hidde mann, W., Niemeyer, C., Henze, G., Feldges, A., Zintl, F., et al. (2000). Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALLBFM 90. Blood 95, 3310–3322. |
| [37] | Schwartz C. L., Thompson E. B., Gelber R. D., et al. (2001). Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J. Clin. Oncol. 19: 1040–1046. |
| [38] | Silverman, L. B., Gelber, R. D., Dalton, V. K., Asselin, B. L., Barr, R. D., Clavell, L. A., Hurwitz, C. A., Moghrabi, A., Samson, Y., Schorin, M. A., et al. (2001). Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97, 1211–1218. |
| [39] | Spirito F. R., Mancini M., Dermi V., et al. (2003). Trisomy 13 in a patient with common acute lymphoblasitc leukemia: description of a case and review of the literature. Cancer Genet Cytogenet. 144: 69-72. |
| [40] | Stanford Children’s Health Network. www.stanfordchildrens.org. |
| [41] | Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2003 Sub (1973-2001). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. Available at: http://www.seer.cancer.gov Accessed February 4, 2005. |
